PharmaGap Inc.’s latest round of animal testing for its lead cancer drug, PhG-alpha, indicates “statistically significant effectiveness” in treating human breast and colon cancer. During testing, mice implanted with cancer tissue and subsequently injected with the drug showed greatly reduced growth of tumours versus mice treated with standard chemotherapy. Ottawa-based PharmaGap says the study indicates that PhG-alpha-1 could be developed into an effective cancer agent. The company continues to analyze data from the study and will release its findings as they become available.